KR900013970A - 개선된 다프토마이신용 희석제제 - Google Patents
개선된 다프토마이신용 희석제제 Download PDFInfo
- Publication number
- KR900013970A KR900013970A KR1019900002861A KR900002861A KR900013970A KR 900013970 A KR900013970 A KR 900013970A KR 1019900002861 A KR1019900002861 A KR 1019900002861A KR 900002861 A KR900002861 A KR 900002861A KR 900013970 A KR900013970 A KR 900013970A
- Authority
- KR
- South Korea
- Prior art keywords
- daphtomycin
- dextrose
- mannitol
- solution
- hydroxymethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (9)
- 활성 성분으로 다프토마이신과, pH를 약6.0 내지 약 8.0으로 유지하기에 충분한 양의 비경구적으로 허용가능한 완충제 및, 하나 이상의 약학적으로 허용 가능한 희석제 또는 부형제를 포함하는 비경구용 제제.
- 제1항에 있어서, 상기 완충제가 이염기성 인산나트륨인 제제.
- 제1항에 있어서, 상기 완충제가 트리스(하이드록시메틸)아미노메탄인 제제.
- 제2항에 있어서, 상기 이염기성 인산나트륨 완충제가 약 0.02 내지 약 0.13밀리몰 농도로 존재하는 제제.
- 제3항에 있어서, 상기 트리스(하이드록시메틸) 아미노메탄 완충제가 약 0.015 내지 0.03 밀리몰 농도로 존재하는 제제.
- 제4항에 있어서, 하기 (a) 내지 (t)를 포함하는 제제 :(a) 다프토마이신 150mg만니톨 50mg이염기성 인산 나트륨 등장 용액(8.73mg/㎖) 10㎖덱스트로즈(5%) 90㎖(b) 다프토마이신 200mg만니톨 66mg이염기성 인산 나트륨 등장 용액(8.73mg/㎖) 13㎖덱스트로즈(5%) 87㎖(c) 다프토마이신 250mg만니톨 82mg이염기성 인산 나트륨 등장 용액(8.73mg/㎖) 16㎖덱스트로즈(5%) 84㎖(d) 다프토마이신 300mg만니톨 100mg이염기성 인산 나트륨 등장 용액(8.73mg/㎖) 20㎖덱스트로즈(5%) 80㎖(e) 다프토마이신 150mg만니톨 50mg이염기성 인산 나트륨 등장 용액(15.76mg/㎖ 10㎖덱스트로즈(5%) 90㎖(f) 다프토마이신 200mg만니톨 60mg이염기성 인산 나트륨 등장 용액(15.76mg/㎖) 13㎖덱스트로즈(5%) 87㎖(g) 다프토마이신 250mg만니톨 82mg이염기성 인산 나트륨 등장 용액(15.76mg/㎖) 16㎖덱스트로즈(5%) 84㎖(h) 다프토마이신 300mg만니톨 100mg이염기성 인산 나트륨 등장 용액(15.76mg/㎖) 20㎖덱스트로즈(5%) 80㎖(i) 다프토마이신 150mg만니톨 50mg트리스(하이드록시메틸)아미노메탄용액(3.30mg/㎖) 10㎖덱스트로즈(5%) 90㎖(j) 다프토마이신 200mg만니톨 66mg트리스(하이드록시메틸)아미노메탄용액(3.30mg/㎖) 13㎖덱스트로즈(5%) 87㎖(k) 다프토마이신 250mg만니톨 82mg트리스(하이드록시메틸)아미노메탄용액(3.30mg/㎖) 16㎖덱스트로즈(5%) 84㎖(l) 다프토마이신 300mg만니톨 100mg트리스(하이드록시메틸)아미노메탄용액(3.30mg/㎖) 20㎖덱스트로즈(5%) 80㎖(m) 다프토마이신 150mg만니톨 50mg트리스(하이드록시메틸)아미노메탄용액(3.74mg/㎖) 10㎖; 또는덱스트로즈(5%) 90㎖(n) 다프토마이신 200mg만니톨 66mg트리스(하이드록시메틸)아미노메탄용액(3.74mg/㎖) 13㎖덱스트로즈(5%) 87㎖(o) 다프토마이신 250mg만니톨 82mg트리스(하이드록시메틸)아미노메탄용액(3.74mg/㎖) 16㎖덱스트로즈(5%) 84㎖(p) 다프토마이신 300mg만니톨 100mg트리스(하이드록시메틸)아미노메탄용액(3.74mg/㎖) 20㎖덱스트로즈(5%) 80㎖(q) 다프토마이신 150mg만니톨 50mg트리스(하이드록시메틸)아미노메탄용액(4.96mg/㎖) 10㎖덱스트로즈(5%) 90㎖(r) 다프토마이신 200mg만니톨 66mg트리스(하이드록시메틸)아미노메탄용액(4.96mg/㎖) 13㎖덱스트로즈(5%) 87㎖(s) 다프토마이신 250mg만니톨 82mg트리스(하이드록시메틸)아미노메탄용액(4.96mg/㎖) 16㎖덱스트로즈(5%) 84㎖(t) 다프토마이신 300mg만니톨 100mg트리스(하이드록시메틸)아미노메탄용액(4.96mg/㎖) 20㎖덱스트로즈(5%) 80㎖
- 적어도 2개의 용기를 포함하는데, 제1용기는 다프토마이신을 함유하고, 제2용기는 혼합했을 때 제1용기중의 다프토마이신 용액의 pH를 약 6.0 내지 약 8.0으로 유지할 수 있는 완충제를 함유하며, 상기 두 용기 각각은 경우에 따라 하나 이상의 약학적으로 허용가능한 담체 또는 부형제를 포함하는, 항생제 다프토마이신 비경구용 제제의 제조용 키트.
- 하나 이상의 약학적으로 허용가능한 희석제 및 부형제로 희석시켰을때의 용액의 pH를 약 6.0 내지 약 8.0으로 제공하기에 충분한 양의 비경구적으로 허용가능한 완충제와 혼합된, 항생 효과량의 항생제 다프토마이신을 포함하는 약학 조성물.
- 다프토마이신과 하나 이상의 약학적으로 허용가능한 희석제 또는 부형제를 혼합함을 포함하는 다프토마이신 비경구용 제제를 제조하는 방법에 있어서, 상기 제제의 pH를 약 6.0 내지 약 8.0으로 유지하기에 충분한 양의 비경구적으로 허용가능한 완충제를 첨가함을 특징으로 하는 다프토마이신 비경구용 제제의 제조 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31924889A | 1989-03-06 | 1989-03-06 | |
US319,248 | 1989-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR900013970A true KR900013970A (ko) | 1990-10-22 |
Family
ID=23241458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900002861A KR900013970A (ko) | 1989-03-06 | 1990-03-05 | 개선된 다프토마이신용 희석제제 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0386951A3 (ko) |
JP (1) | JPH02273623A (ko) |
KR (1) | KR900013970A (ko) |
CN (1) | CN1054537A (ko) |
AU (1) | AU5070890A (ko) |
CA (1) | CA2011365A1 (ko) |
HU (1) | HU204200B (ko) |
IL (1) | IL93618A0 (ko) |
NZ (1) | NZ232763A (ko) |
PT (1) | PT93338A (ko) |
ZA (1) | ZA901622B (ko) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1964557E (pt) * | 1997-11-10 | 2013-02-20 | Sloan Kettering Inst Cancer | Processo para a produção de formulações de trióxido de arsénio |
EP1674107B8 (en) * | 1998-09-25 | 2017-01-25 | Cubist Pharmaceuticals LLC | Use of daptomycin |
CA2355293C (en) | 1998-12-23 | 2005-08-16 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
KR100613136B1 (ko) | 1999-03-03 | 2006-08-17 | 일라이 릴리 앤드 캄파니 | 미셀-형성 계면활성제를 함유하는 에키노칸딘 제약학적조제물 |
US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
KR20090122469A (ko) * | 2000-12-18 | 2009-11-30 | 큐비스트 파마슈티컬즈 인코포레이티드 | 정제된 리포펩티드의 제조 방법 |
WO2002059145A1 (en) * | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
GB0307553D0 (en) * | 2003-04-01 | 2003-05-07 | Novartis Ag | Organic compounds |
WO2011035108A1 (en) * | 2009-09-17 | 2011-03-24 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
EP2504020A4 (en) * | 2009-11-23 | 2013-05-29 | Eagle Pharmaceuticals Inc | DAPTOMYCIN FORMULATIONS |
HUE039967T2 (hu) * | 2009-11-23 | 2019-02-28 | Cubist Pharmaceuticals Llc | Lipopeptid kompozíció és ezzel kapcsolatos eljárások |
CN103429228B (zh) | 2011-01-05 | 2016-10-26 | 赫士睿股份有限公司 | 万古霉素的喷雾干燥 |
US20130172271A1 (en) * | 2012-01-04 | 2013-07-04 | Cynthia Fragale | Pharmaceutical Spray Drying |
CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
CN104511011A (zh) * | 2013-09-29 | 2015-04-15 | 山东新时代药业有限公司 | 一种达托霉素无菌粉末及其制备方法 |
EP3528786B1 (en) | 2016-10-21 | 2023-04-05 | Xellia Pharmaceuticals ApS | Liquid formulations of daptomycin |
US11058745B1 (en) | 2018-10-04 | 2021-07-13 | Good Health, Llc | Stable liquid pharmaceutical compositions of daptomycin |
CN113811290A (zh) | 2019-05-10 | 2021-12-17 | 埃克斯利亚制药有限公司 | 达托霉素水性制剂 |
CA3170514A1 (en) | 2020-03-12 | 2021-09-16 | Baxter International Inc. | Daptomycin formulations containing a combination of sorbitol and mannitol |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3940483A (en) * | 1971-02-05 | 1976-02-24 | E. R. Squibb & Sons, Inc. | Antibiotic compositions and method |
US3928592A (en) * | 1974-02-22 | 1975-12-23 | Lilly Co Eli | Antibiotic pharmaceutical compositions |
IL68700A0 (en) * | 1982-05-21 | 1983-09-30 | Lilly Co Eli | Improvements relating to a-21978c cyclic peptide derivatives and their production |
ATE31023T1 (de) * | 1983-04-28 | 1987-12-15 | Armour Pharma | Pharmazeutische zubereitung mit gehalt an gereinigtem fibrinonectin. |
ZA88227B (en) * | 1987-01-28 | 1988-06-30 | Warner-Lambert Company | Thrombin preparations |
-
1990
- 1990-03-02 EP EP19900302236 patent/EP0386951A3/en not_active Withdrawn
- 1990-03-02 NZ NZ232763A patent/NZ232763A/xx unknown
- 1990-03-02 IL IL93618A patent/IL93618A0/xx unknown
- 1990-03-02 ZA ZA901622A patent/ZA901622B/xx unknown
- 1990-03-02 CA CA002011365A patent/CA2011365A1/en not_active Abandoned
- 1990-03-05 HU HU901311A patent/HU204200B/hu not_active IP Right Cessation
- 1990-03-05 JP JP2053476A patent/JPH02273623A/ja active Pending
- 1990-03-05 CN CN90101144A patent/CN1054537A/zh active Pending
- 1990-03-05 KR KR1019900002861A patent/KR900013970A/ko not_active Application Discontinuation
- 1990-03-05 PT PT93338A patent/PT93338A/pt not_active Application Discontinuation
- 1990-03-05 AU AU50708/90A patent/AU5070890A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HU204200B (en) | 1991-12-30 |
CN1054537A (zh) | 1991-09-18 |
JPH02273623A (ja) | 1990-11-08 |
EP0386951A3 (en) | 1992-05-20 |
CA2011365A1 (en) | 1990-09-06 |
ZA901622B (en) | 1991-11-27 |
EP0386951A2 (en) | 1990-09-12 |
IL93618A0 (en) | 1990-12-23 |
HUT54307A (en) | 1991-02-28 |
PT93338A (pt) | 1990-11-07 |
AU5070890A (en) | 1990-09-06 |
HU901311D0 (en) | 1990-05-28 |
NZ232763A (en) | 1991-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR900013970A (ko) | 개선된 다프토마이신용 희석제제 | |
Lee | Drug-induced hepatotoxicity | |
AU551241B2 (en) | Preparation of liposomal medicaments | |
JPS6485921A (en) | Cyclosporin preparation | |
KR890009383A (ko) | 지방산 합성물 | |
KR910018387A (ko) | 약제학적 화합물 | |
NO873589D0 (no) | Blanding som inneholder ldopa. | |
Daikos et al. | Trimethoprim-sulfamethoxazole in brucellosis | |
KR900005978A (ko) | 키니딘, 아르테미시닌 및 이의 유도체를 사용한 항말라리아 조성물 및 치료방법 | |
KR880013572A (ko) | 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도 | |
CA2074348A1 (en) | Stable compositions for parenteral administration and their use | |
KR950007857A (ko) | 경구투여용 라파마이신 제제 | |
EP0003150B1 (en) | Stabilized aqueous parenteral antibiotic compositions and a process for their preparation | |
Stene-Larsen et al. | Selective vitamin B12 malabsorption in adult coeliac disease: report on three cases with associated autoimmune diseases | |
JPS5221333A (en) | Hydrous insecticidal composition | |
AU2234588A (en) | Administration of extremely low dosages of dideoxynucleoside analogs for treating or preventing AIDS in subjects | |
Earl et al. | Twelve-hourly dosage schedule for oral and intravenous metronidazole | |
DE2233747A1 (de) | Bestaendige waessrige doxycyclinloesung | |
KR850003501A (ko) | 니페디핀 조성물 및 제법 | |
KR910015574A (ko) | 3-피로글루타밀-티아졸리딘-4-카르복실산의 유도체 및 그들의 약리학적 작용 | |
KR890012960A (ko) | 결정성 β-락탐 용매화물 | |
JPS6456622A (en) | Percutaneous absorbefacient base composition | |
Nayak et al. | Drug transfer across rat intestinal musculature after edetic acid treatment | |
MA21895A1 (fr) | Association de vitamine "a" a dose physiologique et differents principes actifs . | |
CA1336412C (en) | Pharmaceutical composition having synergistic effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |